SID 2026Abstract 0650Clinical trial
Sustained wound healing and long-term safety of prademagene zamikeracel in recessive dystrophic epidermolysis bullosa (RDEB)
Five-year results from the VIITAL™ phase 3 trial
Eid E, Pai A, Truesdale A, Abdelwahab S, Gow J, Tang J
SID Annual Meeting 2026Chicago, 13–16 May 2026 · published in JID 21 Jul 2026
Topics: Genetic skin diseaseCosmetic, lasers, scars & wounds
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/j.jid.2026.06.681 · Not in PubMed: details from Crossref